Immunogenicity and Safety of GlaxoSmithKline Biologicals' DTPa-IPV/Hib (Infanrix-IPV+Hib) Vaccine in Healthy Korean Infants.

Trial Profile

Immunogenicity and Safety of GlaxoSmithKline Biologicals' DTPa-IPV/Hib (Infanrix-IPV+Hib) Vaccine in Healthy Korean Infants.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Hib-DTaP-poliovirus vaccine (Primary) ; DTaP poliovirus vaccine; Hib vaccine conjugate; Pneumococcal 11-valent vaccine conjugate; RIX 4414
  • Indications Diphtheria; Haemophilus infections; Pertussis; Pneumococcal infections; Poliomyelitis; Rotavirus infections; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Most Recent Events

    • 27 Jul 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
    • 01 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top